HIGHLIGHTS
en Cáncer de Próstata

ESMO 2019

Highlights comentados por:
Dr. Javier Puente
Director del Instituto de Oncología del Hospital Clínico San Carlos
Biomarcadores

Biomarcadores

845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors